# Cooper Companies, Inc.: financial statements, quarterly COO · Nasdaq · CIK 711404 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Oct 31 Pages: [Overview](/companies/coo.md) · [Financials](/companies/coo/financials.md) · [Filings](/companies/coo/filings.md) · [Insiders](/companies/coo/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/coo/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [927 d](/filings/0001628280-25-055615.md) | [932](/filings/0000711404-25-000015.md) | [943](/filings/0000711404-25-000040.md) | [1,003](/filings/0000711404-25-000051.md) | [1,018 d](/filings/0001628280-25-055615.md) | [965](/filings/0001628280-26-015620.md) | [1,002](/filings/0001628280-26-041305.md) | [1,060](/filings/0001628280-26-061160.md) | [1,065 d](/filings/0001628280-25-055615.md) | [1,024](/filings/0001628280-26-015620.md) | [1,082](/filings/0001628280-26-041305.md) | [1,066](/filings/0001628280-26-061160.md) | | Cost of revenue | $m | [321 d](/filings/0001628280-25-055615.md) | [308](/filings/0000711404-25-000015.md) | [311](/filings/0000711404-25-000040.md) | [340](/filings/0000711404-25-000051.md) | [341 d](/filings/0001628280-25-055615.md) | [305](/filings/0001628280-26-015620.md) | [323](/filings/0001628280-26-041305.md) | [368](/filings/0001628280-26-061160.md) | [414 d](/filings/0001628280-25-055615.md) | [329](/filings/0001628280-26-015620.md) | [346](/filings/0001628280-26-041305.md) | [354](/filings/0001628280-26-061160.md) | | Gross profit | $m | [607 d](/filings/0001628280-25-055615.md) | [624](/filings/0000711404-25-000015.md) | [631](/filings/0000711404-25-000040.md) | [663](/filings/0000711404-25-000051.md) | [678 d](/filings/0001628280-25-055615.md) | [660](/filings/0001628280-26-015620.md) | [679](/filings/0001628280-26-041305.md) | [692](/filings/0001628280-26-061160.md) | [651 d](/filings/0001628280-25-055615.md) | [695](/filings/0001628280-26-015620.md) | [735](/filings/0001628280-26-041305.md) | [712](/filings/0001628280-26-061160.md) | | Research and development | $m | [36.7 d](/filings/0001628280-25-055615.md) | [39.5](/filings/0000711404-25-000015.md) | [38.9](/filings/0000711404-25-000040.md) | [39.0](/filings/0000711404-25-000051.md) | [37.7 d](/filings/0001628280-25-055615.md) | [40.7](/filings/0001628280-26-015620.md) | [45.5](/filings/0001628280-26-041305.md) | [44.6](/filings/0001628280-26-061160.md) | [41.4 d](/filings/0001628280-25-055615.md) | [44.3](/filings/0001628280-26-015620.md) | [42.5](/filings/0001628280-26-041305.md) | [41.6](/filings/0001628280-26-061160.md) | | Selling, general and administrative | $m | [388 d](/filings/0001628280-25-055615.md) | [381](/filings/0000711404-25-000015.md) | [380](/filings/0000711404-25-000040.md) | [381](/filings/0000711404-25-000051.md) | [391 d](/filings/0001628280-25-055615.md) | [388](/filings/0001628280-26-015620.md) | [399](/filings/0001628280-26-041305.md) | [422](/filings/0001628280-26-061160.md) | [419 d](/filings/0001628280-25-055615.md) | [390](/filings/0001628280-26-015620.md) | [676](/filings/0001628280-26-041305.md) | [401](/filings/0001628280-26-061160.md) | | Operating income | $m | [136 d](/filings/0001628280-25-055615.md) | [153](/filings/0000711404-25-000015.md) | [162](/filings/0000711404-25-000040.md) | [193](/filings/0000711404-25-000051.md) | [198 d](/filings/0001628280-25-055615.md) | [182](/filings/0001628280-26-015620.md) | [185](/filings/0001628280-26-041305.md) | [176](/filings/0001628280-26-061160.md) | [140 d](/filings/0001628280-25-055615.md) | [213](/filings/0001628280-26-015620.md) | [(31.0)](/filings/0001628280-26-041305.md) | [222](/filings/0001628280-26-061160.md) | | Interest expense | $m | [26.3 d](/filings/0000711404-23-000072.md) | [29.9](/filings/0000711404-24-000020.md) | [28.9](/filings/0000711404-24-000043.md) | [28.5](/filings/0000711404-25-000051.md) | [27.0 d](/filings/0001628280-25-055615.md) | [26.0](/filings/0001628280-26-015620.md) | [24.2](/filings/0001628280-26-041305.md) | [25.4](/filings/0001628280-26-061160.md) | [24.4 d](/filings/0001628280-25-055615.md) | [22.4](/filings/0001628280-26-015620.md) | [20.9](/filings/0001628280-26-041305.md) | [21.5](/filings/0001628280-26-061160.md) | | Income tax | $m | [21.9 d](/filings/0001628280-25-055615.md) | [38.8](/filings/0000711404-25-000015.md) | [41.1](/filings/0000711404-25-000040.md) | [59.0](/filings/0000711404-25-000051.md) | [51.1 d](/filings/0001628280-25-055615.md) | [49.0](/filings/0001628280-26-015620.md) | [56.8](/filings/0001628280-26-041305.md) | [53.6](/filings/0001628280-26-061160.md) | [32.2 d](/filings/0001628280-25-055615.md) | [61.4](/filings/0001628280-26-015620.md) | [29.5](/filings/0001628280-26-041305.md) | [(231)](/filings/0001628280-26-061160.md) | | Net income | $m | [84.5 d](/filings/0001628280-25-055615.md) | [81.2](/filings/0000711404-25-000051.md) | [88.9](/filings/0000711404-25-000051.md) | [105](/filings/0000711404-25-000051.md) | [118 d](/filings/0001628280-25-055615.md) | [104](/filings/0001628280-26-061160.md) | [87.7](/filings/0001628280-26-061160.md) | [98.3](/filings/0001628280-26-061160.md) | [84.6 d](/filings/0001628280-25-055615.md) | [131](/filings/0001628280-26-061160.md) | [(77.9)](/filings/0001628280-26-061160.md) | [433](/filings/0001628280-26-061160.md) | | Diluted EPS | $ per share | not reported | [0.41](/filings/0000711404-25-000015.md) | [0.44](/filings/0000711404-25-000040.md) | [0.52](/filings/0000711404-25-000051.md) | not reported | [0.52](/filings/0001628280-26-015620.md) | [0.44](/filings/0001628280-26-041305.md) | [0.49](/filings/0001628280-26-061160.md) | not reported | [0.66](/filings/0001628280-26-015620.md) | [(0.40)](/filings/0001628280-26-041305.md) | [2.24](/filings/0001628280-26-061160.md) | | Basic EPS | $ per share | not reported | [0.41](/filings/0000711404-25-000015.md) | [0.45](/filings/0000711404-25-000040.md) | [0.53](/filings/0000711404-25-000051.md) | not reported | [0.52](/filings/0001628280-26-015620.md) | [0.44](/filings/0001628280-26-041305.md) | [0.49](/filings/0001628280-26-061160.md) | not reported | [0.67](/filings/0001628280-26-015620.md) | [(0.40)](/filings/0001628280-26-041305.md) | [2.24](/filings/0001628280-26-061160.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.1](/filings/0001628280-25-055615.md) | [0.1](/filings/0000711404-25-000015.md) | [0.1](/filings/0000711404-25-000040.md) | [0.1](/filings/0000711404-25-000051.md) | [0.1](/filings/0001628280-25-055615.md) | [0.1](/filings/0001628280-26-015620.md) | [0.1](/filings/0001628280-26-041305.md) | [0.1](/filings/0001628280-26-061160.md) | [0.1](/filings/0001628280-26-061160.md) | [0.1](/filings/0001628280-26-015620.md) | [0.1](/filings/0001628280-26-041305.md) | [0.2](/filings/0001628280-26-061160.md) | | Current assets | $bn | [1.7](/filings/0000711404-24-000074.md) | [1.8](/filings/0000711404-24-000020.md) | [1.9](/filings/0000711404-24-000043.md) | [1.9](/filings/0000711404-24-000062.md) | [2.0](/filings/0001628280-25-055615.md) | [2.0](/filings/0000711404-25-000015.md) | [2.1](/filings/0000711404-25-000040.md) | [2.1](/filings/0000711404-25-000051.md) | [2.1](/filings/0001628280-26-061160.md) | [2.1](/filings/0001628280-26-015620.md) | [2.3](/filings/0001628280-26-041305.md) | [2.3](/filings/0001628280-26-061160.md) | | Total assets | $bn | [11.7](/filings/0001628280-25-055615.md) | [12.0](/filings/0000711404-24-000020.md) | [12.0](/filings/0000711404-24-000043.md) | [12.1](/filings/0000711404-24-000062.md) | [12.3](/filings/0001628280-25-055615.md) | [12.2](/filings/0000711404-25-000015.md) | [12.4](/filings/0000711404-25-000040.md) | [12.4](/filings/0000711404-25-000051.md) | [12.4](/filings/0001628280-26-061160.md) | [12.4](/filings/0001628280-26-015620.md) | [12.5](/filings/0001628280-26-041305.md) | [12.7](/filings/0001628280-26-061160.md) | | Current liabilities | $bn | [1.0](/filings/0000711404-24-000074.md) | [1.0](/filings/0000711404-24-000020.md) | [1.0](/filings/0000711404-24-000043.md) | [1.0](/filings/0000711404-24-000062.md) | [1.0](/filings/0001628280-25-055615.md) | [1.0](/filings/0000711404-25-000015.md) | [1.0](/filings/0000711404-25-000040.md) | [1.0](/filings/0000711404-25-000051.md) | [1.1](/filings/0001628280-26-061160.md) | [1.6](/filings/0001628280-26-015620.md) | [1.8](/filings/0001628280-26-041305.md) | [1.9](/filings/0001628280-26-061160.md) | | Total liabilities | $bn | [4.1](/filings/0000711404-24-000074.md) | [4.3](/filings/0000711404-24-000020.md) | [4.2](/filings/0000711404-24-000043.md) | [4.2](/filings/0000711404-24-000062.md) | [4.2](/filings/0001628280-25-055615.md) | [4.1](/filings/0000711404-25-000015.md) | [4.1](/filings/0000711404-25-000040.md) | [4.0](/filings/0000711404-25-000051.md) | [4.2](/filings/0001628280-26-061160.md) | [4.1](/filings/0001628280-26-015620.md) | [4.2](/filings/0001628280-26-041305.md) | [4.3](/filings/0001628280-26-061160.md) | | Long-term debt | $bn | [2.5](/filings/0000711404-24-000074.md) | [2.7](/filings/0000711404-24-000020.md) | [2.7](/filings/0000711404-24-000043.md) | [2.6](/filings/0000711404-24-000062.md) | [2.5](/filings/0001628280-25-055615.md) | [2.5](/filings/0000711404-25-000015.md) | [2.5](/filings/0000711404-25-000040.md) | [2.4](/filings/0000711404-25-000051.md) | [2.5](/filings/0001628280-26-061160.md) | [1.9](/filings/0001628280-26-015620.md) | [1.9](/filings/0001628280-26-041305.md) | [1.9](/filings/0001628280-26-061160.md) | | Current portion of debt | $bn | [0.0](/filings/0000711404-24-000074.md) | [0.0](/filings/0000711404-24-000020.md) | [0.0](/filings/0000711404-24-000043.md) | [0.0](/filings/0000711404-24-000062.md) | [0.0](/filings/0001628280-25-055615.md) | [0.0](/filings/0000711404-25-000015.md) | [0.1](/filings/0000711404-25-000040.md) | [0.0](/filings/0000711404-25-000051.md) | [0.0](/filings/0001628280-26-061160.md) | [0.6](/filings/0001628280-26-015620.md) | [0.6](/filings/0001628280-26-041305.md) | [0.6](/filings/0001628280-26-061160.md) | | Short-term borrowings | $bn | [0.0](/filings/0000711404-24-000074.md) | [0.0](/filings/0000711404-24-000020.md) | [0.0](/filings/0000711404-24-000043.md) | [0.0](/filings/0000711404-24-000062.md) | [0.0](/filings/0001628280-25-055615.md) | [0.0](/filings/0000711404-25-000015.md) | [0.1](/filings/0000711404-25-000040.md) | [0.0](/filings/0000711404-25-000051.md) | [0.0](/filings/0001628280-26-061160.md) | [0.6](/filings/0001628280-26-015620.md) | [0.6](/filings/0001628280-26-041305.md) | [0.6](/filings/0001628280-26-061160.md) | | Shareholders' equity | $bn | [7.6](/filings/0000711404-24-000074.md) | [7.7](/filings/0000711404-24-000020.md) | [7.8](/filings/0000711404-24-000043.md) | [7.9](/filings/0000711404-24-000062.md) | [8.1](/filings/0001628280-25-055615.md) | [8.1](/filings/0000711404-25-000015.md) | [8.3](/filings/0000711404-25-000040.md) | [8.4](/filings/0000711404-25-000051.md) | [8.2](/filings/0001628280-26-061160.md) | [8.4](/filings/0001628280-26-015620.md) | [8.2](/filings/0001628280-26-041305.md) | [8.3](/filings/0001628280-26-061160.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:DebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [174 d](/filings/0001628280-25-055615.md) | [123](/filings/0000711404-25-000015.md) | [111 d](/filings/0000711404-25-000040.md) | [208 d](/filings/0000711404-25-000051.md) | [268 d](/filings/0001628280-25-055615.md) | [191](/filings/0001628280-26-015620.md) | [96.2 d](/filings/0001628280-26-041305.md) | [261 d](/filings/0001628280-26-061160.md) | [248 d](/filings/0001628280-25-055615.md) | [261](/filings/0001628280-26-015620.md) | [183 d](/filings/0001628280-26-041305.md) | [342 d](/filings/0001628280-26-061160.md) | | Capital expenditure | $m | [145 d](/filings/0001628280-25-055615.md) | [118](/filings/0000711404-25-000015.md) | [74.1 d](/filings/0000711404-25-000040.md) | [89.0 d](/filings/0000711404-25-000051.md) | [140 d](/filings/0001628280-25-055615.md) | [89.4](/filings/0001628280-26-015620.md) | [78.1 d](/filings/0001628280-26-041305.md) | [96.9 d](/filings/0001628280-26-061160.md) | [98.0 d](/filings/0001628280-25-055615.md) | [102](/filings/0001628280-26-015620.md) | [86.4 d](/filings/0001628280-26-041305.md) | [68.7 d](/filings/0001628280-26-061160.md) | | Dividends paid | $m | [1.5 d](/filings/0001628280-25-055615.md) | not reported | not reported | [0.0 d](/filings/0000711404-24-000062.md) | [0.0 d](/filings/0001628280-25-055615.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $m | [0.0 d](/filings/0001628280-25-055615.md) | not reported | not reported | [0.0 d](/filings/0000711404-25-000051.md) | [0.0 d](/filings/0001628280-25-055615.md) | [0.0](/filings/0001628280-26-015620.md) | [40.6 d](/filings/0001628280-26-041305.md) | [52.7 d](/filings/0001628280-26-061160.md) | [197 d](/filings/0001628280-25-055615.md) | [92.5](/filings/0001628280-26-015620.md) | [15.5 d](/filings/0001628280-26-041305.md) | [339 d](/filings/0001628280-26-061160.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-01-31) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [199](/filings/0000711404-24-000020.md) | [199](/filings/0000711404-24-000043.md) | [200](/filings/0000711404-24-000062.md) | [200](/filings/0000711404-25-000015.md) | [201](/filings/0000711404-25-000040.md) | [201](/filings/0000711404-25-000051.md) | [201](/filings/0001628280-26-015620.md) | [201](/filings/0001628280-26-041305.md) | [200](/filings/0001628280-26-061160.md) | [197](/filings/0001628280-26-015620.md) | [195](/filings/0001628280-26-041305.md) | [193](/filings/0001628280-26-061160.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 190,155,294 at 2026-09-03, from the cover of the [10-Q filed 2026-09-09](/filings/0001628280-26-061160.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.